Keratoacanthoma - Keratoacantoma
☆ Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
àbhaisteach Keratoacantoma (Keratoacanthoma)
References
Is e tumhair craiceann tric a th’ ann an Keratoacanthoma (KA) a tha ainmeil airson a bhith a’ fàs gu sgiobalta agus an comas a dhol air ais leis fhèin. Mar as trice bidh e a’ tachairt ann am fir nas sine, le craiceann bàn le eachdraidh de mhilleadh grèine. Ged is e toirt air falbh obair-lannsa a’ cleachdadh excision no lannsa micrographic Mohs an làimhseachadh àbhaisteach, tha grunn roghainnean leigheis eile rim faighinn.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Is e tumhair aig ìre ìosal a th’ ann an Keratoacanthoma (KA) a thòisicheas ann an cuid de fàireagan sa chraiceann agus a tha coltach ri squamous cell carcinoma (SCC) fo mhiocroscop. Tha deasbad a’ dol air adhart a thaobh am bu chòir KA a bhith air a sheòrsachadh mar sheòrsa de SCC ionnsaigheach.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Is e Cutaneous squamous cell carcinoma (cSCC) an dàrna seòrsa aillse as cumanta ann an daoine, gu sònraichte am measg dhaoine nas sine. Mar as trice bidh lannsaireachd air a chleachdadh airson cSCC a làimhseachadh, ach airson cuid de dh’ euslaintich nach urrainn obair-lannsa fhaighinn no roghnachadh gun a bhith, faodar beachdachadh air roghainnean eile leithid leigheasan intralesional. Chaidh leigheasan traidiseanta intralesional (methotrexate or 5-fluorouracil) a chleachdadh, ach tha rannsachadh leantainneach ann air dòighean-obrach ùra leithid immunotherapy intralesional agus virotherapy oncolytic. An seo, seallaidh sinn ri diofar leigheasan intralesional airson cSCC, bho dhòighean clasaigeach gu ro-innleachdan as ùire.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Fon mhiocroscop, tha keratoacantoma (keratoacanthoma) glè choltach ri carcinoma cealla squamous. Fhad ‘s a tha cuid de luchd-eòlaiche-eòlais a’ seòrsachadh keratoacantoma (keratoacanthoma) mar eintiteas sònraichte agus chan e malignancy, bidh timcheall air 6% de keratoacantoma (keratoacanthoma) clionaigeach agus eachdraidheil a’ dol air adhart gu aillsean cealla squamous ionnsaigheach agus ionnsaigheach.
○ Diagnosis agus Làimhseachadh
#Dermoscopy
#Skin biopsy